Seagen Inc.
Headquarters country
Netherlands
Registry sponsor category
Industry
- Company name
- Seagen Inc.
- Organisation type
- Industry
- Registered legal name
- SEAGEN B.V.
- Registry sponsor category
- Industry
- Website
- http://www.seattlegenetics.com/
- Seagen Inc.
- Seagen, a wholly owned subsidiary of Pfizer
- Headquarters country
- Netherlands
- Publicly traded (proxy)
- Yes
- Listing at source
- Listed
- SEC filer number (CIK)
- 0001060736
- Legal Entity Identifier (LEI)
- 2549006KAG05LMBMFG37
- Wikidata ID
- Q17155112
Related records
Parent companies (1)
- Pfizer Direct parent
Trials (202)
- A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
- A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib
- A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib on Metformin
- A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma
- A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma
- A Phase 1 Dose-escalation Trial of SGN-75 in CD70-positive Non-Hodgkin Lymphoma or Renal Cell Carcinoma
- A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma
- A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms
- A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma
- A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma
- A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)
- A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)
- A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies
- A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS)
- A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)
- A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
- A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL
- A Safety Study in Patients With Chronic Lymphocytic Leukemia
- A Safety Study of Brentuximab Vedotin in Participants With HIV
- A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome